<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab5">
 <label>Table 5</label>
 <caption>
  <p>Subgroup analysis of objective response rate, full analysis set</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Subgroup</th>
    <th>
     <italic>n</italic>/
     <italic>N</italic>
     <sup>a</sup>
    </th>
    <th>ORR (95% CI), %</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>All evaluable patients in phases 1 + 2</td>
    <td>11/45</td>
    <td>24 (13–40)</td>
   </tr>
   <tr>
    <td colspan="3">Sex</td>
   </tr>
   <tr>
    <td> Men</td>
    <td>8/30</td>
    <td>27 (12–46)</td>
   </tr>
   <tr>
    <td> Women</td>
    <td>3/15</td>
    <td>20 (4–48)</td>
   </tr>
   <tr>
    <td colspan="3">Age group</td>
   </tr>
   <tr>
    <td> &lt; 65 years</td>
    <td>6/16</td>
    <td>38 (15–65)</td>
   </tr>
   <tr>
    <td> ≥ 65 years</td>
    <td>5/29</td>
    <td>17 (6–36)</td>
   </tr>
   <tr>
    <td colspan="3">No. of previous anti-tumor regimens</td>
   </tr>
   <tr>
    <td> 1</td>
    <td>5/19</td>
    <td>26 (9–51)</td>
   </tr>
   <tr>
    <td> 2</td>
    <td>3/9</td>
    <td>33 (8–70)</td>
   </tr>
   <tr>
    <td> 3</td>
    <td>3/10</td>
    <td>30 (7–65)</td>
   </tr>
   <tr>
    <td> ≥ 4</td>
    <td>0/7</td>
    <td>0 (0–41)</td>
   </tr>
   <tr>
    <td colspan="3">Histological classification</td>
   </tr>
   <tr>
    <td> Peripheral T cell lymphoma, NOS</td>
    <td>5/22</td>
    <td>23 (8–45)</td>
   </tr>
   <tr>
    <td> Angioimmunoblastic T cell lymphoma</td>
    <td>6/18</td>
    <td>33 (13–59)</td>
   </tr>
   <tr>
    <td colspan="3">Ann Arbor stage
     <sup>b</sup>
    </td>
   </tr>
   <tr>
    <td> Stage I</td>
    <td>0/1</td>
    <td>0 (0–98)</td>
   </tr>
   <tr>
    <td> Stage II</td>
    <td>2/11</td>
    <td>18 (2–52)</td>
   </tr>
   <tr>
    <td> Stage III</td>
    <td>7/19</td>
    <td>37 (16–62)</td>
   </tr>
   <tr>
    <td> Stage IV</td>
    <td>2/13</td>
    <td>15 (2–45)</td>
   </tr>
   <tr>
    <td colspan="3">ECOG performance status</td>
   </tr>
   <tr>
    <td> 0</td>
    <td>7/27</td>
    <td>26 (11–46)</td>
   </tr>
   <tr>
    <td> 1</td>
    <td>4/18</td>
    <td>22 (6–48)</td>
   </tr>
   <tr>
    <td colspan="3">Target lesion SPD</td>
   </tr>
   <tr>
    <td> &lt; 14 cm
     <sup>2</sup>
    </td>
    <td>8/26</td>
    <td>31 (14–52)</td>
   </tr>
   <tr>
    <td> ≥ 14 cm
     <sup>2</sup>
    </td>
    <td>3/19</td>
    <td>16 (3–40)</td>
   </tr>
   <tr>
    <td colspan="3">LDH</td>
   </tr>
   <tr>
    <td> Low/normal</td>
    <td>9/25</td>
    <td>36 (18–58)</td>
   </tr>
   <tr>
    <td> High</td>
    <td>2/20</td>
    <td>10 (1–32)</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>CI</italic> confidence interval, 
   <italic>ECOG</italic> Eastern Cooperative Oncology Group, 
   <italic>LDH</italic> lactate dehydrogenase, 
   <italic>NOS</italic> not otherwise specified, 
   <italic>ORR</italic> objective response rate, 
   <italic>SPD</italic> sum of the products of the largest diameters of target lesions
  </p>
  <p>
   <sup>a</sup>Number of patients with objective responses divided by the total number of patients in the category
  </p>
  <p>
   <sup>b</sup>Except for transformed mycosis fungoides
  </p>
 </table-wrap-foot>
</table-wrap>
